Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) has been assigned a consensus recommendation of "Buy" from the eight brokerages that are currently covering the company, Marketbeat.com reports. Eight investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $9.00.
A number of research firms have recently issued reports on PYXS. HC Wainwright reiterated a "buy" rating and issued a $7.00 price objective on shares of Pyxis Oncology in a report on Friday, August 16th. Stifel Nicolaus started coverage on shares of Pyxis Oncology in a research report on Thursday, August 8th. They set a "buy" rating and a $10.00 price target on the stock. Finally, Jefferies Financial Group restated a "buy" rating and issued a $10.00 price objective on shares of Pyxis Oncology in a report on Tuesday, May 7th.
Get Our Latest Stock Report on PYXS
Pyxis Oncology Trading Up 2.0 %
Shares of Pyxis Oncology stock traded up $0.07 during trading on Wednesday, reaching $3.51. The stock had a trading volume of 221,445 shares, compared to its average volume of 651,955. The company has a market capitalization of $206.70 million, a price-to-earnings ratio of -2.58 and a beta of 1.28. Pyxis Oncology has a 52 week low of $1.35 and a 52 week high of $6.85. The stock has a fifty day moving average price of $3.43 and a two-hundred day moving average price of $4.16.
Hedge Funds Weigh In On Pyxis Oncology
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. StemPoint Capital LP acquired a new stake in shares of Pyxis Oncology in the first quarter valued at approximately $7,643,000. Ikarian Capital LLC acquired a new stake in Pyxis Oncology during the first quarter worth approximately $7,082,000. Vanguard Group Inc. boosted its holdings in shares of Pyxis Oncology by 7.3% during the first quarter. Vanguard Group Inc. now owns 1,401,425 shares of the company's stock worth $5,970,000 after acquiring an additional 94,740 shares during the period. Millennium Management LLC increased its stake in shares of Pyxis Oncology by 125.3% during the second quarter. Millennium Management LLC now owns 1,336,908 shares of the company's stock worth $4,425,000 after purchasing an additional 743,499 shares during the period. Finally, Blue Owl Capital Holdings LP bought a new position in shares of Pyxis Oncology during the second quarter worth approximately $3,462,000. Institutional investors own 39.09% of the company's stock.
About Pyxis Oncology
(
Get Free ReportPyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Featured Articles
Before you consider Pyxis Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pyxis Oncology wasn't on the list.
While Pyxis Oncology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
